Cited by 5,761Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Open access

Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H.·2006·New England Journal of Medicine

DOI 10.1056/nejmoa061884

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa061884

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citation
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,985

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 4

Brown LF, 1993, Cancer Res, 53, 4727
Kabbinavar FF, 1995, Proc Am Assoc Cancer Res, 36, 488
Borgstrom P, 1999, Anticancer Res, 19, 4203
Miller KD, 2005, Breast Cancer Res Treat, 94, S6

Sorted by citations

Items 201–300 of 1,018

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
Fojo, T., Mailankody, S., & Lo, A. W. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 309
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 311
Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab
Spigel, D. R., Hainsworth, J. D., Yardley, D. A., Raefsky, E. L., Patton, J. F., Peacock, N. W., Farley, C. P., Burris, H. A., & Greco, F. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7353 · Cited by 302
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 308
New Targetable Oncogenes in Non–Small-Cell Lung Cancer
Oxnard, G. R., Binder, A. F., & Janne, P. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9829 · Cited by 304
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway
Zhang, Q., Lu, S.-H., Li, T., Yu, L., Zhang, Y., Zeng, H., Qian, X., Bi, J., & Lin, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1156-5 · Cited by 300
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 293
The incidence of venous thromboembolism among patients with primary lung cancer
Chew, H. K., Davies, A. M., Wun, T., HARVEY, D., Zhou, H., & WHITE, R. H. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02908.x · Cited by 292
Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Heymach, J. V., Johnson, B. E., Prager, D., Csada, E., Roubec, J., Pešek, M., Špásová, I., Belani, C. P., Bodrogi, I., Gadgeel, S. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5122 · Cited by 292
Bevacizumab
Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0317 · Cited by 291
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Natale, R. B., Thongprasert, S., Greco, F. A., Thomas, M., Tsai, C., Sunpaweravong, P., Ferry, D. R., Mulatero, C., Whorf, R. C., Thompson, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5981 · Cited by 290
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 296
Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
Boer, R. H. D., Arrieta, O. G., Yang, C.-H., Gottfried, M., Chan, V. F., Raats, J., de Marinis, F., Abratt, R. P., Wolf, J., Blackhall, F. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5717 · Cited by 287
Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer
Takano, A., Ishikawa, N., Nishino, R., Masuda, K., Yasui, W., Inai, K., Nishimura, H., Ito, H., Nakayama, H., Miyagi, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0016 · Cited by 286
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Horvath, L., Thienpont, B., Zhao, L., Wolf, D. G. F., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 288
Lung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 281
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Tanoue, L. T. (2011) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2011.02.002 · Cited by 286
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
Doebele, R. C., Lu, X. J. D., Sumey, C. J., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 280
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
Shibuya, M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.4.278 · Cited by 280
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 277
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Ranpura, V. N., Hapani, S., Chuang, J., & Wu, S. (2010) · Acta Oncologica · doi:10.3109/02841860903524396 · Cited by 276
EGFR Targeting of Solid Tumors
Rocha‐Lima, C., Soares, H. P., Raez, L. E., & Singal, R. (2007) · Cancer Control · doi:10.1177/107327480701400313 · Cited by 276
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Maitland, M. L., Frankel, P. H., Argiris, A. E., Koczywas, M., Gitlitz, B. J., Thomas, S. P., Espinoza‐Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
Cancer stem cells: implications for the progression and treatment of metastatic disease
Croker, A. K., & Allan, A. L. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00211.x · Cited by 274
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
Hirsch, F. R., Herbst, R. S., Olsen, C. C., Chansky, K., Crowley, J. J., Kelly, K. L., Franklin, W. A., Bunn, P. A., Varella‐Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0111 · Cited by 273
Reinforcement learning design for cancer clinical trials
Zhao, Y., Kosorok, M. R., & Zeng, D. (2009) · Statistics in Medicine · doi:10.1002/sim.3720 · Cited by 281
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
Hirsch, F. R., Varella‐Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., Dziadziuszko, R., Gumerlock, P. H., Chansky, K., West, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm003 · Cited by 270
Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
Lubner, S. J., Mahoney, M. R., Kolesar, J., LoConte, N. K., Kim, G. P., Pitot, H. C., Philip, P. A., Picus, J., Yong, W. P., Horvath, L. G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4075 · Cited by 267
Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression
Pal, S. K., & Hurria, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0579 · Cited by 266
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
Eichler, A. F., Kahle, K. T., Wang, D. L., Joshi, V. A., Willers, H., Engelman, J. A., Lynch, T. J., & Sequist, L. V. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq076 · Cited by 266
Vascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 268
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
Dowlati, A., Gray, R. J., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 264
Self-citation
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
Crinò, L., Dansin, É., Garrido, P., Griesinger, F., Laskin, J. J., Pavlakis, N., Stroiakovski, D., Thatcher, N., Tsai, C., Wu, Y.-L. L. C., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70151-0 · Cited by 261
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor
Park, M. S., PATEL, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., Wang, W., Boonsirikamchai, P., Choi, H., Wang, X., et al. (2011) · Cancer · doi:10.1002/cncr.26098 · Cited by 260
Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer
Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L. L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9331 · Cited by 260
Retracted
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
Dancey, J. E., Dobbin, K. K., Groshen, S. G., Jessup, J. M., Hruszkewycz, A. H., Koehler, M. T., Parchment, R. E., Ratain, M. J., Shankar, L. K., Stadler, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2167 · Cited by 259
Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 259
Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
Kindler, H. L., Karrison, T. G., Gandara, D. R., Lu, C. S., Krug, L. M., Stevenson, J. P., Janne, P. A., Quinn, D. I., Koczywas, M., Brahmer, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5869 · Cited by 257
Self-citation
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Vahid, B., & Marik, P. E. (2008) · CHEST Journal · doi:10.1378/chest.07-0851 · Cited by 254
Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
Scagliotti, G. V., Brodowicz, T., Shepherd, F. A., Zielinski, C. C., Vansteenkiste, J., Manegold, C., Simms, L., Fossella, F. V., Sugarman, K. P., & Belani, C. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f7c6d4 · Cited by 252
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
Abdel-Qadir, H. M., Ethier, J.-L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.002 · Cited by 256
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Jankú, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 258
Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
O'Shannessy, D. J., Yu, G. H., Smale, R., Fu, Y., Singhal, S. K., Thiel, R. P., Somers, E. B., & Vachani, A. (2012) · Oncotarget · doi:10.18632/oncotarget.519 · Cited by 250
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Spano, J., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H. S., Barone, C., Letourneau, R., Bajetta, E., Pithavala, Y. K., Bycott, P. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60661-3 · Cited by 250
Molecular Biology of Lung Cancer
Nana-Sinkam, S. P., & Powell, C. A. (2013) · CHEST Journal · doi:10.1378/chest.12-2346 · Cited by 251
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
Paz-Ares, L. G., Biesma, B., Heigener, D. F., von Pawel, J., Eisen, T., Bennouna, J., Zhang, L., Liao, M., Sun, Y., Gans, S. J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7646 · Cited by 248
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 254
Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
Bender, J. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., Kerbel, R. S., Cooney, E., Stempak, D., Chen, H. X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9230 · Cited by 249
Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer
Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kůta, M., van Klaveren, R. J., Chaudhary, S., Gunther, A., & Shamsili, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1862 · Cited by 247
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
Soria, J., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N. F., Smethurst, D. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 247
Molecular Biology of Lung Cancer: Clinical Implications
Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 251
Therapeutic management options for stage III non-small cell lung cancer
Yoon, S. M., Shaikh, T., & Hallman, M. A. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i1.1 · Cited by 253
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 250
Gene aberrations for precision medicine against lung adenocarcinoma
Saito, M., Shiraishi, K., Kunitoh, H., Takenoshita, S., Yokota, J., & Kohno, T. (2016) · Cancer Science · doi:10.1111/cas.12941 · Cited by 249
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Lü, S., Wu, L., Jian, H., Chen, Y., Wang, Q., Fang, J., Wang, Z., Hu, Y., Sun, M., Han, L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00382-5 · Cited by 246
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 245
Bevacizumab Safety in Patients with Central Nervous System Metastases
Besse, B., Lasserre, S., Compton, P. G., Huang, J. Q., Augustus, S., & Rohr, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2439 · Cited by 238
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
Manegold, C., Dingemans, A. C., Gray, J. E., Nakagawa, K., Nicolson, M. C., Peters, S., Reck, M., Wu, Y.-L. L. C., Brustugun, O. T., Crinò, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 243
Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases
Socinski, M. A., Langer, C. J., Huang, J. E., Kolb, M. M., Compton, P. G., Wang, L. E., & Akerley, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0616 · Cited by 240
Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
Wu, S., Kim, C., Baer, L. N., & Zhu, X. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020167 · Cited by 239
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Jafri, S. H. R., Glass, J., Shi, R., Zhang, S., Prince, M., & Kleiner‐Hancock, H. E. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-87 · Cited by 245
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Murukesh, N., Dive, C., & Jayson, G. C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605483 · Cited by 235
Leptomeningeal disease: current diagnostic and therapeutic strategies
Nayar, G., Ejikeme, T., Chongsathidkiet, P., Elsamadicy, A. A., Blackwell, K., Clarke, J. M., Lad, S. P., & Fecci, P. E. (2017) · Oncotarget · doi:10.18632/oncotarget.20272 · Cited by 239
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
Ranpura, V. N., Pulipati, B., Chu, D., Zhu, X., & Wu, S. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.25 · Cited by 233
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Goss, G. D., Arnold, A., Shepherd, F. A., Dediu, M., Ciuleanu, T., Fenton, D. W., Zukin, M., Walde, D., Laberge, F., Vincent, M. D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9427 · Cited by 234
Targeting tumor angiogenesis with histone deacetylase inhibitors
Ellis, L., Hammers, H. J., & Пили, Р. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.11.012 · Cited by 238
The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel
Ahmed, A. A., Mills, A. D., Ibrahim, A. E. K., Temple, J., Blenkiron, C., Vias, M., Massie, C. E., Iyer, N. G., McGeoch, A. T., Crawford, R., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.014 · Cited by 233
An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
Ye, X., Li, Y., Stawicki, S. S., Couto, S. S., Eastham‐Anderson, J., Kallop, D. Y., Weimer, R. M., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 231
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L. A., Buzenet, G., Koehler, E., Sosman, J. A., Schwartz, L. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9237 · Cited by 234
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
Soria, J., Smit, E. F., Khayat, D., Besse, B., Yang, X., Hsu, C., Reese, D., Wiezorek, J. S., & Blackhall, F. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4847 · Cited by 231
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Zhou, Q. H., Xu, C., Cheng, Y., Liu, Y., Chen, G., Cui, J., Yang, N., Song, Y., Li, X., Lü, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.005 · Cited by 236
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Wang, Y., Sung, C. W., Dartois, C., Ramchandani, R., Booth, B. P., Rock, E. P., & Gobburu, J. V. S. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.64 · Cited by 237
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
Thunnissen, E., Kerr, K. M., Herth, F. J. F., Lantuéjoul, S., Papotti, M. G., Rintoul, R. C., Rossi, G., Skov, B. G., Weynand, B., Bubendorf, L., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.017 · Cited by 228
Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Besse, B., Moulec, S. L., Mazières, J., Senellart, H., Barlési, F., CHOUAID, C., Dansin, É., Berard, H., Falchero, L., Gervais, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2082 · Cited by 227
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Friedlander, M. L., Hancock, K. C., Rischin, D., Messing, M. J., Stringer, C. A., Matthys, G. M., Ma, B., Hodge, J. P., & Lager, J. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.033 · Cited by 226
Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capó, A., Germonpré, P. R., Eberhardt, W., Stockman, P. K., Kennedy, S. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6015 · Cited by 226
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
Spigel, D. R., Townley, P., Waterhouse, D. M., Fang, L., Adiguzel, I., Huang, J. E., Karlin, D. A., Faoro, L. N., Scappaticci, F. A., & Socinski, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3423 · Cited by 226
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
Zheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 229
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Hu, X., Cao, J., Hu, W., Wu, C., Pan, Y., Cai, L., Tong, Z., Wang, S., Li, J., Wang, Z., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-820 · Cited by 225
Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens
Loo, P. S., Thomas, S. C., Nicolson, M. C., Fyfe, M. N., & Kerr, K. M. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d40fac · Cited by 225
DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
Li, J., Sainson, R. C. A., Oon, C. E., Turley, H., Leek, R., Sheldon, H., Bridges, E., Shi, W., Snell, C. E., Bowden, E. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1704 · Cited by 234
Autophagy in the physiological endometrium and cancer
Devis, L., Eritja, N., Davis, M. L., Matías‐Guiu, X., & Llobet‐Navàs, D. (2020) · Autophagy · doi:10.1080/15548627.2020.1752548 · Cited by 232
Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications
Soultati, A. S., Mountzios, G., Avgerinou, C., Papaxoinis, G., Pectasides, D. G., Dimopoulos, M. A., & PAPADIMITRIOU, C. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.002 · Cited by 221
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Heymach, J. V., Paz-Ares, L. G., de Braud, F., Sebastian, M., Stewart, D. J., Eberhardt, W., Ranade, A. A., Cohen, G. L., Trigo, J. M., Sandler, A. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3138 · Cited by 221
Self-citation
Recent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 222
Self-citation
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L. E., Kefford, R. F., Atkins, M. B., Leming, P. D., & Kirkwood, J. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1529 · Cited by 220
Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Dahlberg, S. E., Sandler, A. B., Brahmer, J. R., Schiller, J. H., & Johnson, D. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4482 · Cited by 220
Self-citation
Antiangiogenic Therapy for Cancer: An Update
Al-Husein, B. A., Abdalla, M., Trepte, M., DeRemer, D. L., & Somanath, P. R. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1147 · Cited by 223
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Blumenthal, G. M., Karuri, S. W., Zhang, H., Zhang, L., Khozin, S., Kazandjian, D. G., Tang, S. W., Sridhara, R., Keegan, P., & Pazdur, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0489 · Cited by 218
Vascular Complications of Cancer Chemotherapy
Cameron, A. C., Touyz, R. M., & Lang, N. N. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.12.023 · Cited by 217
Tumor-derived exosomes in cancer progression and treatment failure
Yu, S., Cao, H., Shen, B., & Feng, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6022 · Cited by 218
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Demedts, I., Vermaelen, K. Y., & van Meerbeeck, J. P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00105009 · Cited by 216
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
Papadimitrakopoulou, V. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825493eb · Cited by 220

Authors: Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H.
Affiliations: Vanderbilt University (US)
Dana-Farber Cancer Institute (US)
University of Missouri (US)
Johns Hopkins University (US)
University of Wisconsin–Madison (US)
University Hospitals of Cleveland (US)
ORCID: Sandler, Alan
Gray, Robert
Brahmer, Julie
Schiller, Joan H.
Dowlati, Afshin
Johnson, David H.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-12-14
Volume: 355
Issue: 24
Pages: 2542-2550
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa061884
OpenAlex: W2145835533
Cited by: 5,761
References: 24
Citations by year: 2026: 49 · 2025: 71 · 2024: 112 · 2023: 135 · 2022: 177 · 2021: 183 · 2020: 180 · 2019: 227 · 2018: 257 · 2017: 278 · 2016: 321 · 2015: 389 · 2014: 400 · 2013: 461 · 2012: 513
FWCI: 299.17
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (U10CA066636, CA-23318, CA49957, U10CA016116, CA66636, U10CA012046, U10CA014548, CA-16116, CA14548, U10CA031946, CA21076, U10CA049957, U10CA021076, U10CA023318, U10CA021115, CA 21115, CA-31946, CA12046)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, bevacizumab, paclitaxel, carboplatin, combination chemotherapy, vascular endothelial growth factor inhibition, overall survival, progression-free survival, pulmonary hemorrhage
MeSH terms: Bevacizumab, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Paclitaxel, Disease-Free Survival, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks